Zobrazeno 1 - 10 of 37 pro vyhledávání: '"Mary M. Sugrue"'
2
Akademický článek
p53-induced growth arrest is regulated by the mitochondrial SirT3 deacetylase.
Autor: SiDe Li, Michaela Banck, Shiraz Mujtaba, Ming-Ming Zhou, Mary M Sugrue, Martin J Walsh
Publikováno v: PLoS ONE, Vol 5, Iss 5, p e10486 (2010)
A hallmark of p53 function is to regulate a transcriptional program in response to extracellular and intracellular stress that directs cell cycle arrest, apoptosis, and cellular senescence. Independent of the role of p53 in the nucleus, some of the a
Externí odkaz: https://doaj.org/article/c30b04160d5e467aa3d9d29f41bb6c0d
Zobrazit plný text záznamu
3
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
Autor: Steven D. Gore, Katharina Götze, Uwe Platzbecker, Pierre Fenaux, Charikleia Kelaidi, Cecile Bally, Najla Al Ali, Esther Oliva, Lionel Ades, Norbert Vey, Ulrich Germing, Mikkael A. Sekeres, Thomas Prebet, R. Komrokji, Thomas Cluzeau, Mary M. Sugrue, Sophie Park
Publikováno v: Oncotarget
// Thomas Prebet 1 , Thomas Cluzeau 2,* , Sophie Park 3,4,* , Mikkael A. Sekeres 5 , Ulrich Germing 6 , Lionel Ades 4,7 , Uwe Platzbecker 8 , Katharina Gotze 9 , Norbert Vey 4,10 , Esther Oliva 11 , Mary M. Sugrue 12 , Cecile Bally 4 , Charikleia Kel
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6697e620146eed05bd5c4ebd9f31060
http://europepmc.org/articles/PMC5669859
Zobrazit plný text záznamu
4
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States
Autor: Mary M. Sugrue, Xiaomei Ma, Bart L. Scott, David P. Steensma, Pavel Kiselev, Arlene S. Swern
Publikováno v: BMJ Open
ObjectivesTreatment patterns for patients with myelodysplastic syndromes (MDS) outside clinical trials are not well described. Our objective was to evaluate treatment patterns and patient characteristics that influence time to disease-modifying thera
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72b1bd3f39ae597a1d5241d007cec868
https://pubmed.ncbi.nlm.nih.gov/30037860
Zobrazit plný text záznamu
5
Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies
Autor: Roger M. Lyons, Lewis R. Silverman, Ravi Vij, Magnus Tobiasson, Nora Tu, David L. Grinblatt, Hamid Sayar, Mary M. Sugrue, Albert Fliss, Rami S. Komrokji, Arlene S. Swern
Publikováno v: The oncologist. 23(2)
Background After erythropoiesis-stimulating agent (ESA) failure, lenalidomide and hypomethylating agents are the only remaining treatment options for most patients with lower-risk myelodysplastic syndromes (LR-MDS). Optimal choice of these agents as
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b7cda2c3f68681bc7bd32f9e0a2170d
https://pubmed.ncbi.nlm.nih.gov/29118268
Zobrazit plný text záznamu
7
Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash
Autor: Dianna Gary, Arlene S. Swern, John Freeman, Mary M. Sugrue, Lilia Weiss
Publikováno v: Therapeutics and Clinical Risk Management
Lilia Weiss,1 Dianna Gary,1 Arlene S Swern,2 John Freeman,1 Mary M Sugrue3 1Global Drug Safety, Celgene Corporation, Summit, 2Biometrics, Celgene Corporation, Berkeley Heights, 3Medical Affairs, Celgene Corporation, Summit, NJ, USA Background: Lenali
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3195c9dbc0364b4ae9304c8c8852f1c1
https://www.dovepress.com/real-world-analysis-of-the-celgene-global-drug-safety-database-early-d-peer-reviewed-article-TCRM
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje